We are live on ! Find out more
ACHN

Achillion Pharmaceuticals
ACHN

Delisted

ACHN was delisted on the 27th of January, 2020.

Back to rankings

147 hedge funds and large institutions have $852M invested in Achillion Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 55 increasing their positions, 44 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

178% more call options, than puts

Call options by funds: $10M | Put options by funds: $3.6M

25% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 44

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

1% less capital invested

Capital invested by funds: $858M → $852M (-$5.15M)

4% less funds holding

Funds holding: 153 → 147 (-6)

15% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 20

Holders
147
Holders Change
-6
Holders Change %
-3.92%
% of All Funds
3.92%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
17
Increased
55
Reduced
44
Closed
20
Calls
$10M
Puts
$3.6M
Net Calls
+$6.4M
Net Calls Change
-$4.11M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$11.9M
2
Norges Bank
Norges Bank
Norway
+$6.26M
3
CAM
Cormorant Asset Management
Massachusetts
+$4.34M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.91M
5
O
OrbiMed
New York
+$1.39M

Top Sellers

Rank Fund Capital Flow
1
JHIU
Janus Henderson Investors US
Colorado
-$9.15M
2
State Street
State Street
Massachusetts
-$6.17M
3
Millennium Management
Millennium Management
New York
-$5.73M
4
OAM
Oxford Asset Management
United Kingdom
-$4.7M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.59M
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
26
Invesco
Georgia
$6.05M -$2.24M -261,258 -25%
Norges Bank
27
Norges Bank
Norway
$5.96M +$6.26M +729,372 +2,117%
JP Morgan Chase
28
JP Morgan Chase
New York
$5.73M -$2.82M -328,516 -31%
SDIC
29
South Dakota Investment Council
South Dakota
$5.23M -$351K -40,900 -6%
Asset Management One
30
Asset Management One
Japan
$4.54M -$1.02M -119,176 -17%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$4.22M +$2.22K +259 +0%
Marshall Wace
32
Marshall Wace
United Kingdom
$4.22M -$3.1M -361,591 -40%
Bank of America
33
Bank of America
North Carolina
$3.9M +$35.3K +4,119 +0.8%
TCIM
34
TIAA CREF Investment Management
New York
$3.76M -$364K -42,479 -8%
BIM
35
BlackRock Investment Management
Delaware
$3.41M +$288K +33,620 +8%
BG
36
Bellevue Group
Switzerland
$3.28M – – –
Charles Schwab
37
Charles Schwab
California
$3.27M +$242K +28,264 +7%
PP
38
PDT Partners
New York
$2.23M +$6K +700 +0.2%
GC
39
Guggenheim Capital
Illinois
$2.17M -$436K -50,820 -15%
QI
40
QS Investors
New York
$2.17M – – –
RPAM
41
Rhenman & Partners Asset Management
Sweden
$2.08M – – –
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$1.92M -$25.7K -3,000 -1%
DCM
43
DAFNA Capital Management
California
$1.84M – – –
CS
44
Credit Suisse
Switzerland
$1.59M +$279K +32,554 +19%
AllianceBernstein
45
AllianceBernstein
Tennessee
$1.56M – – –
UBS Group
46
UBS Group
Switzerland
$1.51M +$86.7K +10,109 +6%
AA
47
ALPS Advisors
Colorado
$1.5M +$328K +38,285 +25%
GAM
48
Gotham Asset Management
New York
$1.5M -$3.11M -362,333 -65%
SIM
49
Spark Investment Management
New York
$1.48M +$634K +73,900 +64%
Swiss National Bank
50
Swiss National Bank
Switzerland
$1.48M +$30.9K +3,600 +2%
1
2
3 4 5

ACHN Hedge Fund Activity: Q2 2016 in Review

147 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q2 2016, worth a combined $852M — down 0.6% from $858M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of ACHN and 17 opened new positions — a net loss of 3 holders — while 44 trimmed existing stakes and 55 added.

The largest buyer was Goldman Sachs, adding an estimated $11.9M. The largest seller was Janus Henderson Investors US, cutting an estimated $9.15M.

  • 147 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q2 2016, down from 153 in Q1 2016.
  • Funds reported $852M of Achillion Pharmaceuticals stock for Q2 2016, down 0.6% quarter-over-quarter.
  • 17 funds opened new Achillion Pharmaceuticals positions in Q2 2016 and 20 closed out, a net change of -3 holders.
  • The largest Achillion Pharmaceuticals buyer in Q2 2016 was Goldman Sachs, an estimated $11.9M added.
  • The largest Achillion Pharmaceuticals seller in Q2 2016 was Janus Henderson Investors US, an estimated $9.15M sold.

Based on aggregated 13F filings for Q2 2016.